niacin and lovastatin

niacin has been researched along with lovastatin in 103 studies

Research

Studies (103)

Timeframe	Studies, this research(%)	All Research%
pre-1990	13 (12.62)	18.7374
1990's	48 (46.60)	18.2507
2000's	31 (30.10)	29.6817
2010's	11 (10.68)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Ekins, S; Williams, AJ; Xu, JJ	1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL	1
Nguyen, TT; O'Brien, T; Silverberg, JD	1
McIntyre, TH; Shapiro, ML; Whitney, EJ; Wirebaugh, SR	1
Brown, BG	1
Henkin, Y; Hurst, DC; Oberman, A; Segrest, JP	1
Hambrecht, R; Kübler, W; Schuler, G; Tischbirek, K; von Hodenberg, E	1
Szamosi, A	1
Erkelens, DW	1
Eisenberg, JM; Glick, H; Jacobson, TA; Kinosian, B; Koffer, H; Schulman, KA; Willian, MK	1
Albers, JJ; Bisson, BD; Brown, G; Dodge, HT; Fisher, LD; Fitzpatrick, VF; Kaplan, C; Lin, JT; Schaefer, SM; Zhao, XQ	1
Diehl, JC; Havel, RJ; Kane, JP; Malloy, MJ; Phillips, NR; Ports, TA	1
Adams, M; Dell, RB; Goldberg, IJ; Goodman, DS; Holleran, S; Palmer, RH; Ramakrishnan, R	1
Bacon, SP; Cope, R; Illingworth, DR	1
Stoy, DB	1
Costa, C; Guarini, G; Santese, D; Trimarco, C; Vitaliano, E	1
Illingworth, DR	1
Hunninghake, DB	1
Bewley, DZ; Lamkin, GE; Stein, EA	1
Reaven, P; Witztum, JL	1
Nikkilä, EA; Tikkanen, MJ	1
Perry, RS	1
Brewer, HB; Hoeg, JM; Starzl, TE	1
Bailey, KR; Brewer, HB; Hoeg, JM; Maher, MB	1
Kane, JP; Kunitake, ST; Malloy, MJ; Tun, P	1
De Boer, HH; Hendriks, T; Van Niekerk, JL	1
Bell, HH; Chiarelli, T; Dittmeier, G; Vacek, JL; White, J	1
Lees, AM; Lees, RS	1
Albers, JJ; Brown, BG; Hillger, L; Poulin, D; Zhao, XQ	1
Hewett, JE; Lal, SM; Petroski, GF; Ross, G; Van Stone, JC	1
Benson, VV; Borok, GM; Dudl, RJ; Epstein, A; Epstein, RS; Heys, JF; Menzin, J; Oster, G; Quinn, V	1
Coates, PM; Cortner, JA; Jarvik, GP; Liacouras, CA	1
Hunninghake, DB; Probstfield, JL	1
Dujovne, CA; Frost, PH; Greguski, RA; Illingworth, DR; Knopp, RH; Mitchel, YB; Stein, EA; Tun, P; Zupkis, RV	1
Bays, H; Lansing, AM	1
Albers, JJ; Brown, BG; Dowdy, A; Fisher, LD; Hillger, LA; Sniderman, AD; Stewart, BF; Zhao, XQ	1
Hathaway, SC; Paat, JJ; Paterson, RW; Steele, GH; Wong, JG	1
Hodgson, JM; Marks, SJ; Matthews, PG; Myers, KA; Wahlqvist, ML	1
Albers, JJ; Bisson, B; Brown, BG; Fisher, L; Hillger, L; Sacco, D; Zhao, XQ	1
Grundy, SM; Vega, GL	2
Feher, MD; Knight, BL; Lant, AF; Mayne, PD; Patel, DD; Soutar, AK; Webb, JC	1
Heudebert, GR; Hiatt, J; Schectman, G; Van Ruiswyk, J	1
Ayaori, M; Nakamura, H	1
Abel, RB; Argoff, CE; Di Bisceglie, AM; Grewal, RP; Higgins, JJ; Parker, CC; Patterson, MC; Pentchev, PG; Schiffmann, R; Yu, K	1
Hartz, A; Hiatt, J; Schectman, G	1
Benson, V; Borok, GM; Dudl, RJ; Epstein, AM; Epstein, RS; Heyse, JF; Menzin, J; Oster, G; Quinn, V	1
Auwerx, J; Fruchart, JC; Staels, B; Van Tol, A	1
Bambauer, R; Müller, UA; Schiel, R	1
O'Connor, PJ; Rush, WA; Trence, DL	1
Avery, BR	1
Albers, JJ; Bardsley, J; Brown, BG; Dowdy, A; Hillger, LA; Knopp, RH; Maher, VM; Poulin, D; Zhao, XQ	1
Grundy, SM	2
Albers, JJ; Brown, BG; Brunzell, JD; Davis, JW; Maher, VM; Poulin, D; Rocha, A; Zambon, A	1
Albers, J; Brown, BG; Chait, A; Cheung, M; DeAngelis, D; Dowdy, A; Fisher, LD; Frohlich, J; Heise, N; Zhao, XQ	1
Wehmeier, T; Ziajka, PE	1
Sinzinger, H	1
Gordon, BR; Saal, SD	1
Brown, BG; Brunzell, JD; Hokanson, JE; Zambon, A	1
Bilbao, JM; Hill, MD	1
Azen, SP; Hodis, HN; Mack, WJ; Selzer, RH; Shircore, AM; Xiang, M	1
Brown, BG; Brunzell, JD; Deeb, SS; Hokanson, JE; Zambon, A	1
Sprecher, DL	1
Pearson, TA	1
Bays, HE; Berra, K; Favrot, LK; Guyton, JR; Harper, WL; Kashyap, ML; Kerzner, B; Kwiterovich, PO; McGovern, ME; Nash, SD; Simmons, PD; Toth, PD	1
Stein, EA	1
Anderson, LM; Calvert, RJ; Diwan, BA; Kritchevsky, D; Ramakrishna, G; Tepper, S	1
Kashyap, ML; Moon, YS	1
Chong, PH; Yim, BT	1
Bays, HE; Crouse, JR; Dujovne, CA; Hutcheson, AG; Kashyap, ML; McGovern, ME; White, TE	1
Brazg, R; Hunninghake, DB; Koren, M; McGovern, ME; Murdock, D; Pearson, T; Weiss, S	1
Lipton, AM; Lutjohann, D; Moore, C; Svetlik, D; Vega, GL; Von Bergmann, K; Weiner, MF	1
Baskin, F; Fang, X; Hynan, LS; Moore, CB; Rosenberg, RN; Vega, GL; Weiner, M	1
Anderson, LM; Calvert, RJ; Diwan, BA; Kritchevsky, D; Tepper, S	1
Thompson, PD	1
Bays, HE; McGovern, ME	2
Corbelli, J; Crouse, JR; Insull, W; McGovern, ME; Schrott, H; Thompson, P; Zieve, F	1
Bays, HE	1
Rubenfire, M	1
Kamanna, VS; Kashyap, ML; Meyers, CD	1
Al-Shaer, MH	1
Brown, BG; Brunzell, JD; Hokanson, JE; Motulsky, AG; Zambon, A	1
Huang, CH; Lai, WT; Lin, TH; Sheu, SH; Su, HM; Voon, WC; Yen, HW	1
Anderson, LM; Calvert, RJ; Kammouni, W; Kritchevsky, D; Tepper, S	1
Alsheikh-Ali, AA; Karas, RH	1
Gupta, R; Hira, HS; Kumar, N; Mohan, B; Panwar, RB; Sharma, DR; Sharma, M; Sharma, SK; Singh, V	1
Cefali, E; Menon, R; Tolbert, D	1
Ai, M; Asztalos, BF; Barrett, PH; Buchsbaum, A; Diffenderfer, MR; Dolnikowski, GG; Horvath, KV; Lamon-Fava, S; Lichtenstein, AH; Matthan, NR; Nyaku, M; Otokozawa, S; Schaefer, EJ	1
Charland, SL; Malone, DC	1
Ballantyne, CM; Creager, MA; Dale, RA; Hiatt, WR; Hirsch, AT; Mohler, ER; Rajagopalan, S; Regensteiner, JG; Rooke, T; Treat-Jacobson, D	1
Bullano, MF; Chang, CL; Cziraky, MJ; Gandhi, SK; Kamat, SA	1
Brinton, EA; Jiang, P; Kashyap, ML; Padley, RJ; Thakkar, RB; Vo, AN	1
Inamadugu, JK; Mullangi, R; Nallapati, IK; Pilli, NR; Rao, JV	1

Reviews

25 review(s) available for niacin and lovastatin

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management. JAMA, 1990, Dec-19, Volume: 264, Issue:23 Topics: Anticholesteremic Agents; Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Cost-Benefit Analysis; Drug Therapy, Combination; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Niacin; Probucol; Sensitivity and Specificity	1990
Drug therapy of hypercholesterolemia. Clinical chemistry, 1988, Volume: 34, Issue:8B Topics: Bile Acids and Salts; Cholesterol, LDL; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Lovastatin; Niacin	1988
Contemporary recommendations for evaluating and treating hyperlipidemia. Clinical pharmacy, 1986, Volume: 5, Issue:2 Topics: Clofibrate; Dextrothyroxine; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins; Lovastatin; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Phenotype; Probucol	1986
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis. Circulation, 1984, Volume: 69, Issue:5 Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type IV; Hyperlipoproteinemias; Lactation; Lipoproteins; Lovastatin; Naphthalenes; Niacin; Pentanoic Acids; Pregnancy; Pregnancy Complications; Probucol; Tangier Disease; Triglycerides	1984
The treatment of familial hypercholesterolaemia by partial ileal bypass surgery. A review of the literature. The Netherlands journal of medicine, 1984, Volume: 27, Issue:1 Topics: Anticholesteremic Agents; Cholesterol; Clofibrate; Diarrhea; Heterozygote; Homozygote; Humans; Hyperlipoproteinemia Type II; Ileum; Lovastatin; Methods; Naphthalenes; Niacin; Postoperative Complications	1984
Familial combined hyperlipidemia in children: clinical expression, metabolic defects, and management. Current problems in pediatrics, 1994, Volume: 24, Issue:9 Topics: Adolescent; Adult; Biological Transport; Child; Child, Preschool; Cholestyramine Resin; Diet, Fat-Restricted; Humans; Hyperlipidemia, Familial Combined; Lipoproteins; Lovastatin; Niacin	1994
Impact of intensive lipid modulation on angiographically defined coronary disease: clinical implications. Southern medical journal, 1994, Volume: 87, Issue:2 Topics: Angiography; Clinical Trials as Topic; Colestipol; Coronary Disease; Humans; Hypercholesterolemia; Lipids; Lovastatin; Niacin; Random Allocation	1994
[Progress in the treatment of atherosclerotic vascular diseases]. Nihon rinsho. Japanese journal of clinical medicine, 1993, Volume: 51, Issue:8 Topics: Angioplasty, Balloon, Coronary; Arteriosclerosis; Atherectomy; Diet; Humans; Ion Exchange Resins; Life Style; Lovastatin; Niacin; Risk Factors	1993
Cholesterol management in patients with heart disease. Emphasizing secondary prevention to increase longevity. Postgraduate medicine, 1997, Volume: 102, Issue:2 Topics: Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Longevity; Lovastatin; Niacin; Simvastatin	1997
Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia. The American journal of cardiology, 1998, Feb-26, Volume: 81, Issue:4A Topics: Cholesterol, HDL; Cholesterol, VLDL; Clinical Trials as Topic; Consensus Development Conferences as Topic; Coronary Disease; Drug Therapy, Combination; Exercise; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Triglycerides; Weight Loss	1998
Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men. The American journal of cardiology, 1998, Feb-26, Volume: 81, Issue:4A Topics: Apolipoproteins B; Cholesterol, LDL; Cholesterol, VLDL; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Insulin Resistance; Lipoproteins; Lipoproteins, IDL; Lipoproteins, LDL; Lovastatin; Male; Niacin	1998
Use of niacin, statins, and resins in patients with combined hyperlipidemia. The American journal of cardiology, 1998, Feb-26, Volume: 81, Issue:4A Topics: Anticholesteremic Agents; Apolipoproteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Cohort Studies; Colestipol; Coronary Disease; Drug Therapy, Combination; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lovastatin; Niacin; Risk Factors; Triglycerides	1998
Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design. The Canadian journal of cardiology, 1998, Volume: 14 Suppl A Topics: Adult; Aged; Antioxidants; Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Myocardial Revascularization; Niacin; Simvastatin; Treatment Outcome; Vitamins	1998
Peripheral neuropathy and lipid-lowering therapy. Southern medical journal, 1998, Volume: 91, Issue:7 Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Naphthalenes; Niacin; Peripheral Nervous System Diseases; Pravastatin; Pyrroles; Simvastatin	1998
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis]. Deutsche medizinische Wochenschrift (1946), 1998, Sep-18, Volume: 123, Issue:38 Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis	1998
Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review. The American journal of cardiology, 2000, Dec-21, Volume: 86, Issue:12A Topics: Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Drug Combinations; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Myocardial Infarction; Niacin; Ultrasonography	2000
Divergent approaches to the treatment of dyslipidemia with low levels of high-density lipoprotein cholesterol. The American journal of cardiology, 2000, Dec-21, Volume: 86, Issue:12A Topics: Cholesterol, HDL; Clinical Trials as Topic; Drug Combinations; Ethanol; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Life Style; Lovastatin; Niacin	2000
Managing dyslipidemia in the high-risk patient. The American journal of cardiology, 2002, Mar-07, Volume: 89, Issue:5A Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States	2002
Niacin extended-release/lovastatin: combination therapy for lipid disorders. Expert opinion on pharmacotherapy, 2002, Volume: 3, Issue:12 Topics: Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Niacin	2002
Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia. The Annals of pharmacotherapy, 2003, Volume: 37, Issue:1 Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Niacin	2003
What's new in lipid management? Pharmacotherapy, 2003, Volume: 23, Issue:9 Pt 2 Topics: Bile Acids and Salts; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Metabolism; Lovastatin; Niacin	2003
Extended-release niacin/lovastatin: the first combination product for dyslipidemia. Expert review of cardiovascular therapy, 2004, Volume: 2, Issue:4 Topics: Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Humans; Lovastatin; Niacin	2004
Niacin therapy in atherosclerosis. Current opinion in lipidology, 2004, Volume: 15, Issue:6 Topics: Anti-Inflammatory Agents; Arteriosclerosis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Lovastatin; Niacin; Randomized Controlled Trials as Topic	2004
Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy. Current medical research and opinion, 2010, Volume: 26, Issue:2 Topics: Algorithms; Azetidines; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Female; Humans; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Niacin; Prognosis; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Simvastatin	2010

Trials

33 trial(s) available for niacin and lovastatin

Article	Year
Effect of lovastatin or niacin combined with colestipol and regression of coronary atherosclerosis. European heart journal, 1992, Volume: 13 Suppl B Topics: Apolipoprotein A-I; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Humans; Lovastatin; Male; Middle Aged; Niacin	1992
[Angiographic regression of coronary atheromatosis]. Lakartidningen, 1991, Apr-10, Volume: 88, Issue:15 Topics: Angiography; Anticholesteremic Agents; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged; Niacin; Remission Induction	1991
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. The New England journal of medicine, 1990, Nov-08, Volume: 323, Issue:19 Topics: Adult; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Angiography; Coronary Disease; Diet; Double-Blind Method; Drug Therapy, Combination; Humans; Lovastatin; Male; Middle Aged; Multivariate Analysis; Niacin	1990
Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA, 1990, Dec-19, Volume: 264, Issue:23 Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Niacin; Radiographic Image Interpretation, Computer-Assisted; Triglycerides	1990
[Effects on lipid metabolism of inhibitors of cholesterol synthesis]. La Clinica terapeutica, 1988, Apr-15, Volume: 125, Issue:1 Topics: Aged; Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Clofibrate; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lipid Metabolism; Lipids; Lovastatin; Male; Middle Aged; Niacin; Triglycerides	1988
Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia. The American journal of cardiology, 1995, Jul-15, Volume: 76, Issue:3 Topics: Aged; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Niacin; Prospective Studies; Treatment Outcome	1995
Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease. Observations from the FATS Trial. Familial Atherosclerosis Treatment Study. Annals of the New York Academy of Sciences, 1995, Jan-17, Volume: 748 Topics: Adult; Colestipol; Coronary Disease; Diet, Fat-Restricted; Humans; Lovastatin; Male; Middle Aged; Niacin	1995
Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 1995, Volume: 25, Issue:4 Topics: Adult; Anticholesteremic Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Transplantation; Lovastatin; Male; Niacin; Postoperative Complications; Prospective Studies; Triglycerides; Uric Acid	1995
A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS). Controlled clinical trials, 1995, Volume: 16, Issue:1 Topics: Adult; Aged; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Costs and Cost Analysis; Follow-Up Studies; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Middle Aged; Niacin; Patient Selection; Prospective Studies; Risk Factors; Treatment Outcome	1995
Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Archives of internal medicine, 1994, Jul-25, Volume: 154, Issue:14 Topics: Adult; Aged; Female; Humans; Hypercholesterolemia; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Niacin	1994
Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. Journal of the American College of Cardiology, 1994, Mar-15, Volume: 23, Issue:4 Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Apolipoproteins B; Cholesterol, LDL; Colestipol; Coronary Angiography; Coronary Disease; Double-Blind Method; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Niacin; Treatment Outcome	1994
Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B. Circulation, 1993, Volume: 88, Issue:6 Topics: Adult; Apolipoproteins B; Colestipol; Coronary Disease; Coronary Vessels; Double-Blind Method; Exercise Test; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Niacin; Radiography	1993
The effect of cholesterol-lowering agents on hepatic and plasma cholesterol in Niemann-Pick disease type C. Neurology, 1993, Volume: 43, Issue:1 Topics: Adolescent; Adult; Anticholesteremic Agents; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Dimethyl Sulfoxide; Drug Therapy, Combination; Humans; Liver; Lovastatin; Male; Niacin; Niemann-Pick Diseases	1993
Cholesterol-reduction intervention study (CRIS): a randomized trial to assess effectiveness and costs in clinical practice. Archives of internal medicine, 1996, Apr-08, Volume: 156, Issue:7 Topics: Adult; Aged; Anticholesteremic Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Niacin; Treatment Outcome	1996
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis. The International journal of artificial organs, 1995, Volume: 18, Issue:12 Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Longitudinal Studies; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Quality of Life	1995
Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. The American journal of cardiology, 1997, Jul-15, Volume: 80, Issue:2 Topics: Cholesterol, LDL; Colestipol; Cross-Over Studies; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged; Niacin; Patient Compliance	1997
Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design. The Canadian journal of cardiology, 1998, Volume: 14 Suppl A Topics: Adult; Aged; Antioxidants; Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Myocardial Revascularization; Niacin; Simvastatin; Treatment Outcome; Vitamins	1998
Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation, 1999, Apr-20, Volume: 99, Issue:15 Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Centrifugation, Density Gradient; Chemical Phenomena; Chemistry, Physical; Cholesterol, LDL; Colestipol; Combined Modality Therapy; Coronary Artery Disease; Drug Therapy, Combination; Humans; Hypolipidemic Agents; Lipase; Lipids; Lipolysis; Lipoproteins; Liver; Lovastatin; Male; Middle Aged; Niacin	1999
Efficacy of two lipid-lowering treatments on quantitative coronary angiographic endpoints. Cardiovascular drugs and therapy, 2000, Volume: 14, Issue:4 Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Colestipol; Coronary Angiography; Drug Combinations; Female; Humans; Hypolipidemic Agents; Longitudinal Studies; Lovastatin; Male; Middle Aged; Niacin; Randomized Controlled Trials as Topic; Sensitivity and Specificity	2000
Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation, 2001, Feb-13, Volume: 103, Issue:6 Topics: Analysis of Variance; Cholesterol, HDL; Colestipol; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; Genotype; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipase; Lipoproteins, HDL; Lipoproteins, LDL; Liver; Lovastatin; Male; Middle Aged; Niacin; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Promoter Regions, Genetic; Regression Analysis	2001
Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. The American journal of cardiology, 2002, Mar-15, Volume: 89, Issue:6 Topics: Adult; Aged; Aged, 80 and over; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoprotein(a); Lovastatin; Male; Middle Aged; Niacin; Risk Factors; Survival Analysis; Treatment Outcome	2002
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). The American journal of cardiology, 2003, Mar-15, Volume: 91, Issue:6 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Time Factors	2003
A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clinical cardiology, 2003, Volume: 26, Issue:3 Topics: Analysis of Variance; Chi-Square Distribution; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Niacin; Probability; Sensitivity and Specificity; Treatment Outcome	2003
Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Archives of neurology, 2003, Volume: 60, Issue:4 Topics: Aged; Alzheimer Disease; Brain; Cholesterol 24-Hydroxylase; Female; Humans; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Simvastatin; Steroid Hydroxylases; Treatment Outcome	2003
Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients. Neurology, 2003, Jun-24, Volume: 60, Issue:12 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Blood Platelets; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Niacin; Pravastatin; Protein Processing, Post-Translational; Simvastatin; Single-Blind Method	2003
Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Archives of internal medicine, 2004, May-24, Volume: 164, Issue:10 Topics: Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Niacin; Probability; Reference Values; Risk Assessment; Severity of Illness Index; Treatment Outcome	2004
Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. The American journal of cardiology, 2004, Aug-01, Volume: 94, Issue:3 Topics: Administration, Oral; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Hyperlipidemias; Liver Function Tests; Lovastatin; Male; Middle Aged; Muscular Diseases; Niacin; Patient Compliance; Probability; Prospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome	2004
Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy. Journal of internal medicine, 2006, Volume: 259, Issue:4 Topics: Adult; Analysis of Variance; Apolipoproteins B; Colestipol; Coronary Angiography; Coronary Stenosis; Drug Therapy, Combination; Dyslipidemias; Genetic Predisposition to Disease; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Niacin; Pharmacogenetics; Treatment Outcome	2006
Randomized comparative study of the effects of treatment with once-daily, niacin extended-release/lovastatin and with simvastatin on lipid profile and fibrinolytic parameters in Taiwan. The Kaohsiung journal of medical sciences, 2006, Volume: 22, Issue:6 Topics: Aged; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Male; Middle Aged; Niacin; Simvastatin; Triglycerides	2006
Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric study. Vascular health and risk management, 2006, Volume: 2, Issue:1 Topics: Apolipoprotein A-I; Apolipoproteins B; Asian People; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Female; Humans; Hypolipidemic Agents; India; Lipoprotein(a); Lovastatin; Male; Middle Aged; Niacin; Time Factors; Triglycerides	2006
The comparative bioavailability of an extended-release niacin and lovastatin fixed dose combination tablet versus extended-release niacin tablet, lovastatin tablet and a combination of extended-release niacin tablet and lovastatin tablet. Biopharmaceutics & drug disposition, 2007, Volume: 28, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Female; Flushing; Humans; Lovastatin; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Niacin; Niacinamide; Nicotinic Acids; Pyridones; Tablets; Time Factors; Vitamin B Complex	2007
Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arteriosclerosis, thrombosis, and vascular biology, 2008, Volume: 28, Issue:9 Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoprotein B-100; Apolipoprotein B-48; Cholesterol, HDL; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Kinetics; Lipid Metabolism; Lovastatin; Male; Middle Aged; Niacin; Treatment Outcome; Triglycerides	2008
Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease. Vascular medicine (London, England), 2010, Volume: 15, Issue:3 Topics: Aged; Delayed-Action Preparations; Drug Therapy, Combination; Exercise Test; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intermittent Claudication; Lovastatin; Male; Middle Aged; Niacin; Peripheral Arterial Disease; Treatment Outcome; Vasodilator Agents	2010

Other Studies

46 other study(ies) available for niacin and lovastatin

Article	Year
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics. PloS one, 2016, Volume: 11, Issue:10 Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat	2016
Nicotinic acid-induced toxicity associated with cytopenia and decreased levels of thyroxine-binding globulin. Mayo Clinic proceedings, 1992, Volume: 67, Issue:5 Topics: Aged; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Humans; Hypothyroidism; Leukopenia; Lovastatin; Male; Middle Aged; Niacin; Thrombocytopenia; Thyroid Function Tests; Thyroxine-Binding Proteins	1992
A retrospective review of the use of lipid-lowering agents in combination, specifically, gemfibrozil and lovastatin. Pharmacotherapy, 1992, Volume: 12, Issue:6 Topics: Aged; Alanine Transaminase; Cholestyramine Resin; Colestipol; Creatine Kinase; Drug Interactions; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Lipids; Lovastatin; Male; Middle Aged; Niacin; Retrospective Studies	1992
Niacin revisited: clinical observations on an important but underutilized drug. The American journal of medicine, 1991, Volume: 91, Issue:3 Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Cholesterol, HDL; Cholesterol, VLDL; Delayed-Action Preparations; Diabetes Complications; Drug Therapy, Combination; Female; Heart Transplantation; Humans; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Niacin; Retrospective Studies	1991
[Type III hyperlipoproteinemia in monoclonal IgM gammopathy]. Deutsche medizinische Wochenschrift (1946), 1991, Nov-08, Volume: 116, Issue:45 Topics: Adult; Bezafibrate; Cholesterol; Dietary Fats; Female; Humans; Hypergammaglobulinemia; Hyperlipoproteinemia Type III; Immunoglobulin lambda-Chains; Immunoglobulin M; Lipids; Lovastatin; Niacin; Triglycerides	1991
Choice of cholesterol-lowering drugs. The Medical letter on drugs and therapeutics, 1991, Jan-11, Volume: 33, Issue:835 Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibrate; Colestipol; Fish Oils; Gemfibrozil; Humans; Lovastatin; Neomycin; Niacin; Probucol	1991
Combination drug therapy with HMG CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia. Cardiology, 1990, Volume: 77 Suppl 4 Topics: Cholestyramine Resin; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Niacin; Simvastatin	1990
Lack of effect of lovastatin therapy on the parameters of whole-body cholesterol metabolism. The Journal of clinical investigation, 1990, Volume: 86, Issue:3 Topics: Adult; Aged; Cholesterol; Colestipol; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Metabolic Clearance Rate; Middle Aged; Niacin	1990
Regression of tendon xanthomas in patients with familial hypercholesterolemia treated with lovastatin. Southern medical journal, 1990, Volume: 83, Issue:9 Topics: Achilles Tendon; Adult; Cholesterol, LDL; Colestipol; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Niacin; Radiography; Remission Induction; Tendons; Wolman Disease	1990
Controlling cholesterol with drugs. The American journal of nursing, 1989, Volume: 89, Issue:12 Topics: Anticholesteremic Agents; Cholestyramine Resin; Drug Therapy, Combination; Humans; Hypercholesterolemia; Lovastatin; Niacin	1989
Current and new therapy for hypercholesterolemia. The Journal of the American Osteopathic Association, 1988, Volume: 88, Issue:7 Topics: Anticholesteremic Agents; Colestipol; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Niacin; Probucol	1988
Lovastatin alone and in combination for treatment of primary hypercholesterolemia. Progress in clinical and biological research, 1988, Volume: 255 Topics: Adult; Aged; Anion Exchange Resins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Niacin; Patient Compliance	1988
Lovastatin, nicotinic acid, and rhabdomyolysis. Annals of internal medicine, 1988, Oct-01, Volume: 109, Issue:7 Topics: Adult; Drug Therapy, Combination; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Niacin; Rhabdomyolysis	1988
Current pharmacologic treatment of elevated serum cholesterol. Circulation, 1987, Volume: 76, Issue:3 Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Drug Tolerance; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Probucol; Simvastatin; Triglycerides	1987
Liver transplantation for treatment of cardiovascular disease: comparison with medication and plasma exchange in homozygous familial hypercholesterolemia. The American journal of cardiology, 1987, Mar-01, Volume: 59, Issue:6 Topics: Child; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Coronary Disease; Homozygote; Humans; Hyperlipoproteinemia Type II; Liver Transplantation; Lovastatin; Male; Naphthalenes; Niacin; Plasma Exchange; Skin Diseases; Xanthomatosis	1987
Comparison of six pharmacologic regimens for hypercholesterolemia. The American journal of cardiology, 1987, Apr-01, Volume: 59, Issue:8 Topics: Adult; Aged; Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Neomycin; Niacin; Retrospective Studies	1987
Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia. Annals of internal medicine, 1987, Volume: 107, Issue:5 Topics: Adult; Aged; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Colestipol; Drug Therapy, Combination; Female; Heterozygote; Homozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Niacin; Polyamines	1987
Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. The New England journal of medicine, 1995, Sep-07, Volume: 333, Issue:10 Topics: Drug Interactions; Female; Humans; Itraconazole; Lovastatin; Middle Aged; Niacin; Rhabdomyolysis	1995
Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician. Archives of internal medicine, 1994, Jul-25, Volume: 154, Issue:14 Topics: Coronary Disease; Humans; Hypercholesterolemia; Lipoproteins; Lovastatin; Niacin	1994
Fish oil (omega-3 fatty acids) in treatment of hypertriglyceridemia. A practical approach for the primary care physician. The Journal of the Kentucky Medical Association, 1994, Volume: 92, Issue:3 Topics: Aged; Clofibrate; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Lipids; Lovastatin; Niacin; Primary Health Care	1994
Improvement in arterial stiffness during hypolipidaemic therapy is offset by weight gain. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1993, Volume: 17, Issue:10 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Arteries; Blood Pressure; Body Mass Index; Carotid Artery, Common; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Dietary Fats; Female; Femoral Artery; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Niacin; Simvastatin; Triglycerides; Ultrasonography; Weight Gain	1993
Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Archives of internal medicine, 1994, Jan-10, Volume: 154, Issue:1 Topics: Gemfibrozil; Humans; Hypolipoproteinemias; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Niacin	1994
Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia. Atherosclerosis, 1993, Volume: 103, Issue:2 Topics: Adolescent; Adult; Anticholesteremic Agents; Child; Cholesterol; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Niacin; Pedigree; Polymorphism, Genetic; Probucol; Receptors, LDL; Simvastatin	1993
Combination drug therapy for hypercholesterolemia. The trade-off between cost and simplicity. Archives of internal medicine, 1993, Aug-09, Volume: 153, Issue:15 Topics: Aged; Algorithms; Anticholesteremic Agents; Decision Trees; Drug Costs; Drug Therapy, Combination; Female; Hospitals, Veterans; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Midwestern United States; Niacin; Probability; Prospective Studies; Treatment Outcome	1993
Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium and lovastatin) for treating hypercholesterolemia in veterans. The American journal of cardiology, 1993, Apr-01, Volume: 71, Issue:10 Topics: Age Factors; Anticholesteremic Agents; Cholesterol; Humans; Hypercholesterolemia; Lovastatin; Middle Aged; Niacin; Patient Compliance; Prospective Studies; Psyllium; Regression Analysis; Treatment Refusal; United States; Veterans	1993
Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat. Israel journal of medical sciences, 1996, Volume: 32, Issue:6 Topics: Actins; Animals; Apolipoproteins; Cholestyramine Resin; Clofibrate; Fenofibrate; Gene Expression Regulation; Hypolipidemic Agents; Intestinal Mucosa; Lipid Metabolism; Lipoproteins, HDL; Liver; Lovastatin; Male; Niacin; Probucol; Rats; Rats, Wistar; Simvastatin	1996
Relative effectiveness of niacin and lovastatin for treatment of dyslipidemias in a health maintenance organization. The Journal of family practice, 1997, Volume: 44, Issue:5 Topics: Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Female; Follow-Up Studies; Health Maintenance Organizations; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Midwestern United States; Niacin; Patient Compliance; Triglycerides	1997
Treatment of the patient with primary familial heterozygous hypercholesterolemia. The Journal of cardiovascular nursing, 1995, Volume: 9, Issue:2 Topics: Aged; Colestipol; Coronary Disease; Diet, Fat-Restricted; Drug Therapy, Combination; Exercise; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Niacin; Patient Compliance; Weight Loss	1995
Immunoadsorption and dextran sulfate cellulose LDL-apheresis for severe hypercholesterolemia: the Rogosin Institute experience 1982-1992. Transfusion science, 1993, Volume: 14, Issue:3 Topics: Adult; Aged; Blood Component Removal; Child; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Coronary Disease; Dextran Sulfate; Humans; Hypercholesterolemia; Immunosorbent Techniques; Lovastatin; Middle Aged; Niacin; Pilot Projects	1993
Case of the month: February 1999--54 year old man with severe muscle weakness. Brain pathology (Zurich, Switzerland), 1999, Volume: 9, Issue:3 Topics: Biopsy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Muscle Weakness; Muscle, Skeletal; Myoglobinuria; Niacin; Rhabdomyolysis	1999
Alterations in membrane-bound and cytoplasmic K-ras protein levels in mouse lung induced by treatment with lovastatin, cholestyramine, or niacin: effects are highly mouse strain dependent. Biochemical pharmacology, 2002, Jul-01, Volume: 64, Issue:1 Topics: Animals; Body Weight; Cell Membrane; Cholesterol; Cholestyramine Resin; Cytoplasm; Genes, ras; Hypolipidemic Agents; Lovastatin; Lung; Mice; Mice, Inbred C57BL; Niacin; Triglycerides	2002
Three new drugs for hyperlipidemia. The Medical letter on drugs and therapeutics, 2003, Mar-03, Volume: 45, Issue:1151 Topics: Azetidines; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Intestinal Absorption; Lovastatin; Muscular Diseases; Niacin	2003
Three new drugs for hyperlipidemia. Connecticut medicine, 2003, Volume: 67, Issue:5 Topics: Azetidines; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Niacin	2003
Treatment with lovastatin, cholestyramine or niacin alters K-ras membrane association in mouse lung in a strain-dependent manner: results in females. Biochemical pharmacology, 2003, Aug-01, Volume: 66, Issue:3 Topics: Animals; Anticholesteremic Agents; Body Weight; Cell Membrane; Cholestyramine Resin; Cytosol; Female; Lipids; Lovastatin; Lung; Male; Mice; Mice, Inbred C57BL; Niacin; Proto-Oncogene Mas; ras Proteins; Sex Factors	2003
Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Preventive cardiology, 2003,Fall, Volume: 6, Issue:4 Topics: Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Combinations; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Niacin; Particle Size; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin	2003
Is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome? American heart journal, 2005, Volume: 149, Issue:3 Topics: Drug Combinations; Humans; Lovastatin; Metabolic Syndrome; Niacin; Uric Acid	2005
Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin. Preventive cardiology, 2005,Fall, Volume: 8, Issue:4 Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Niacin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome	2005
Elevated K-ras activity with cholestyramine and lovastatin, but not konjac mannan or niacin in lung--importance of mouse strain. Biochemical pharmacology, 2006, Dec-15, Volume: 72, Issue:12 Topics: Animals; Anticholesteremic Agents; Blotting, Western; Body Weight; Cholesterol; Cholestyramine Resin; Electrophoresis, Agar Gel; Lovastatin; Lung; Male; Mannans; Mice; Mice, Inbred C57BL; Niacin; ras Proteins; Species Specificity	2006
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). The American journal of cardiology, 2007, Feb-01, Volume: 99, Issue:3 Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver Diseases; Lovastatin; Niacin; Pravastatin; Prevalence; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States; United States Food and Drug Administration	2007
Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population. Current medical research and opinion, 2011, Volume: 27, Issue:5 Topics: Aged; Anticholesteremic Agents; Azetidines; Databases, Factual; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Humans; Lovastatin; Male; Middle Aged; Niacin; Patient Compliance; Retrospective Studies; Simvastatin; Time Factors	2011
Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2011, Jun-01, Volume: 11, Issue:3 Topics: Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Female; Flushing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Medication Adherence; Middle Aged; Niacin; Simvastatin	2011
Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. Biomedical chromatography : BMC, 2012, Volume: 26, Issue:4 Topics: Chromatography, Liquid; Humans; Hypolipidemic Agents; Limit of Detection; Lovastatin; Male; Niacin; Simvastatin; Tandem Mass Spectrometry	2012

chemdatabank.com